• Promising new preclinical data to support human trial
• Results support sustained activity
• Acts as predicted in skin layers

Noxopharm Limited (ASX:NOX) has announced promising new preclinical data for its cutaneous lupus drug candidate SOF-SKN. Following the successful completion of the Phase 1 HERACLES trial, the company investigated the ideal dosing regimen for SOF-SKN, examining the uptake and retention of the active ingredient SOF-16 in both normal and disease-like skin. The results showed a half-life of approximately 3.5 days for SOF-16 in the skin, with the drug remaining predominantly in the target epidermis and dermis layers and minimal systemic absorption. This extended skin residence time could allow for less frequent dosing and improved patient adherence. Noxopharm is now preparing to engage a CRO to support the next steps towards a human trial for SOF-SKN, which is initially targeting the chronic inflammation caused by cutaneous lupus erythematosus (CLE). The company believes the Sofra technology platform, of which SOF-SKN is a part, has potential applications in a wide range of immune-related diseases.

Noxopharm is now in the process of engaging a Contract Research Organisation (CRO) to support preparations for a human trial for SOF-SKN. The company strongly believes the SOF-SKN approach could provide a solution to millions of people suffering from chronic inflammatory skin conditions and will press ahead as they compile their data package in preparation for a trial and regulatory submissions.